|
1
|
High-throughput oncogene mutation profiling in human cancer.
|
Nat Genet
|
2007
|
12.68
|
|
2
|
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
|
J Clin Oncol
|
2003
|
11.33
|
|
3
|
PDGFRA activating mutations in gastrointestinal stromal tumors.
|
Science
|
2003
|
11.11
|
|
4
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
J Clin Oncol
|
2003
|
9.72
|
|
5
|
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2009
|
8.69
|
|
6
|
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
|
Lancet
|
2012
|
8.00
|
|
7
|
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
|
Lancet
|
2007
|
6.76
|
|
8
|
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
|
J Clin Oncol
|
2008
|
6.43
|
|
9
|
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
|
N Engl J Med
|
2010
|
6.28
|
|
10
|
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
|
J Clin Oncol
|
2008
|
6.11
|
|
11
|
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
|
J Clin Oncol
|
2006
|
6.00
|
|
12
|
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
|
Ann Intern Med
|
2006
|
4.52
|
|
13
|
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
|
J Clin Oncol
|
2008
|
4.10
|
|
14
|
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
|
J Clin Oncol
|
2010
|
4.01
|
|
15
|
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
|
J Clin Oncol
|
2008
|
3.64
|
|
16
|
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
|
Cancer Chemother Pharmacol
|
2009
|
3.53
|
|
17
|
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2007
|
3.40
|
|
18
|
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
|
Lancet Oncol
|
2007
|
3.38
|
|
19
|
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
|
Nature
|
2012
|
3.24
|
|
20
|
Major response to imatinib mesylate in KIT-mutated melanoma.
|
J Clin Oncol
|
2008
|
3.16
|
|
21
|
Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
|
Cancer
|
2014
|
2.94
|
|
22
|
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
|
J Surg Oncol
|
2009
|
2.88
|
|
23
|
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
|
J Clin Oncol
|
2002
|
2.85
|
|
24
|
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
|
Proc Natl Acad Sci U S A
|
2009
|
2.84
|
|
25
|
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
|
J Clin Oncol
|
2006
|
2.81
|
|
26
|
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
|
Proc Natl Acad Sci U S A
|
2010
|
2.68
|
|
27
|
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
|
J Clin Oncol
|
2006
|
2.66
|
|
28
|
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2005
|
2.47
|
|
29
|
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
|
J Clin Oncol
|
2011
|
2.46
|
|
30
|
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
|
Lancet Oncol
|
2013
|
2.42
|
|
31
|
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
|
Cancer
|
2002
|
2.17
|
|
32
|
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
|
J Clin Oncol
|
2013
|
2.11
|
|
33
|
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
|
J Clin Oncol
|
2009
|
2.07
|
|
34
|
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
|
Cancer Res
|
2006
|
2.04
|
|
35
|
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
|
J Clin Oncol
|
2005
|
1.98
|
|
36
|
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
|
Pediatr Blood Cancer
|
2009
|
1.94
|
|
37
|
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
|
Clin Cancer Res
|
2007
|
1.94
|
|
38
|
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
|
Clin Cancer Res
|
2010
|
1.89
|
|
39
|
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
|
Ann Surg Oncol
|
2011
|
1.86
|
|
40
|
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
|
J Clin Oncol
|
2012
|
1.84
|
|
41
|
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).
|
Oncogene
|
2004
|
1.82
|
|
42
|
Soft tissue sarcomas of adults: state of the translational science.
|
Clin Cancer Res
|
2003
|
1.81
|
|
43
|
Imatinib targeting of KIT-mutant oncoprotein in melanoma.
|
Clin Cancer Res
|
2008
|
1.73
|
|
44
|
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
|
J Natl Cancer Inst
|
2008
|
1.63
|
|
45
|
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.
|
Breast Cancer Res Treat
|
2003
|
1.60
|
|
46
|
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
|
Eur J Cancer
|
2012
|
1.57
|
|
47
|
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
|
Eur J Cancer
|
2006
|
1.55
|
|
48
|
Small molecule tyrosine kinase inhibitor and depression.
|
J Clin Oncol
|
2008
|
1.51
|
|
49
|
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
|
Clin Cancer Res
|
2002
|
1.48
|
|
50
|
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
|
Cancer
|
2014
|
1.43
|
|
51
|
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
|
AJR Am J Roentgenol
|
2007
|
1.40
|
|
52
|
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
|
Clin Cancer Res
|
2009
|
1.38
|
|
53
|
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
|
Cancer
|
2011
|
1.38
|
|
54
|
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
|
Cancer
|
2012
|
1.36
|
|
55
|
A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
|
Cancer J
|
2002
|
1.33
|
|
56
|
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
|
Clin Cancer Res
|
2008
|
1.33
|
|
57
|
Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
|
Radiology
|
2005
|
1.32
|
|
58
|
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
|
J Clin Oncol
|
2007
|
1.28
|
|
59
|
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.
|
J Clin Invest
|
2007
|
1.26
|
|
60
|
Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.
|
J Am Coll Surg
|
2012
|
1.24
|
|
61
|
Myeloid growth factors. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2007
|
1.23
|
|
62
|
Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes.
|
Oncogene
|
2005
|
1.21
|
|
63
|
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
|
Clin Cancer Res
|
2004
|
1.19
|
|
64
|
Leiomyosarcoma of the inferior vena cava: survival after aggressive management.
|
Ann Surg Oncol
|
2007
|
1.10
|
|
65
|
Multimodality treatment of mesenteric desmoid tumours.
|
Eur J Cancer
|
2008
|
1.09
|
|
66
|
Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.
|
Int J Cancer
|
2010
|
1.08
|
|
67
|
Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
|
Cancer Res
|
2004
|
1.08
|
|
68
|
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
|
Blood
|
2004
|
1.07
|
|
69
|
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
|
Invest New Drugs
|
2011
|
1.07
|
|
70
|
Imaging features of bone metastases in patients with gastrointestinal stromal tumors.
|
Diagn Interv Radiol
|
2012
|
1.06
|
|
71
|
Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
|
Eur J Cancer
|
2009
|
1.04
|
|
72
|
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
|
PLoS One
|
2012
|
1.03
|
|
73
|
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
|
J Clin Oncol
|
2008
|
1.03
|
|
74
|
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
|
Ann Surg
|
2013
|
1.03
|
|
75
|
Aberrant AKT activation drives well-differentiated liposarcoma.
|
Proc Natl Acad Sci U S A
|
2011
|
1.00
|
|
76
|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
|
J Clin Oncol
|
2003
|
1.00
|
|
77
|
Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
|
J Clin Oncol
|
2009
|
1.00
|
|
78
|
Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.
|
Ann Surg Oncol
|
2009
|
1.00
|
|
79
|
Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
|
J Clin Oncol
|
2005
|
0.99
|
|
80
|
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
|
Cancer
|
2003
|
0.97
|
|
81
|
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
|
Clin Cancer Res
|
2005
|
0.96
|
|
82
|
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
|
Cancer
|
2013
|
0.95
|
|
83
|
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
|
Cancer Chemother Pharmacol
|
2002
|
0.95
|
|
84
|
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
|
Cancer
|
2012
|
0.95
|
|
85
|
Myeloid growth factors.
|
J Natl Compr Canc Netw
|
2009
|
0.94
|
|
86
|
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
|
Cancer
|
2007
|
0.92
|
|
87
|
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
|
Cancer
|
2015
|
0.90
|
|
88
|
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
|
Clin Cancer Res
|
2013
|
0.89
|
|
89
|
Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.
|
Arch Pathol Lab Med
|
2010
|
0.89
|
|
90
|
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
|
Clin Cancer Res
|
2002
|
0.89
|
|
91
|
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
|
BMC Cancer
|
2014
|
0.88
|
|
92
|
Modifying phase I methodology to facilitate enrolment of molecularly selected patients.
|
Eur J Cancer
|
2013
|
0.88
|
|
93
|
Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy.
|
Eur Radiol
|
2004
|
0.86
|
|
94
|
Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
|
Semin Oncol
|
2009
|
0.86
|
|
95
|
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
|
Am J Med
|
2004
|
0.85
|
|
96
|
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
|
Cancer Treat Rev
|
2008
|
0.85
|
|
97
|
Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
|
Clin Cancer Res
|
2013
|
0.85
|
|
98
|
A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
|
Oncologist
|
2002
|
0.85
|
|
99
|
Gastrointestinal stromal tumors (GISTs).
|
Curr Opin Gastroenterol
|
2004
|
0.84
|
|
100
|
Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
|
BMC Cancer
|
2014
|
0.84
|
|
101
|
Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
|
Oncologist
|
2002
|
0.83
|
|
102
|
Challenges in the development of platelet growth factors: low expectations for low counts.
|
Curr Hematol Rep
|
2002
|
0.81
|
|
103
|
Clinical benefits of epoetin alfa therapy in patients with lung cancer.
|
Clin Lung Cancer
|
2002
|
0.80
|
|
104
|
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.
|
Clin Adv Hematol Oncol
|
2009
|
0.80
|
|
105
|
Myeloid growth factors clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2005
|
0.80
|
|
106
|
Update on new diagnostic and therapeutic approaches for sarcomas.
|
Clin Adv Hematol Oncol
|
2005
|
0.79
|
|
107
|
Cancer- and treatment-related anemia.
|
J Natl Compr Canc Netw
|
2005
|
0.79
|
|
108
|
Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
|
Clin J Oncol Nurs
|
2005
|
0.79
|
|
109
|
GIST 1, chemotherapy 0, with a brand new hitter up next.
|
Cancer Invest
|
2002
|
0.78
|
|
110
|
Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
|
Leuk Lymphoma
|
2009
|
0.77
|
|
111
|
c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
|
J Pathol
|
2014
|
0.75
|
|
112
|
OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease.
|
Eur J Cancer
|
2003
|
0.75
|
|
113
|
The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.
|
Semin Oncol
|
2011
|
0.75
|
|
114
|
Current management of metastatic gastrointestinal stromal tumor: a case report.
|
Clin Adv Hematol Oncol
|
2003
|
0.75
|
|
115
|
Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
|
Best Pract Res Clin Haematol
|
2005
|
0.75
|